title: Changes in plasma lecithin: cholesterol acyltransferase activity, HDL(2), HDL(3) amounts and compositions in patients with chronic renal failure after different times of hemodialysis.
abstract: The aim of this study was to investigate the effect of hemodialysis duration on HDL(2) and HDL(3) compositions and lecithin:cholesterol acyltransferase (LCAT) activity in 58 patients on acetate hemodialysis using cuprophane membrane, after different periods of dialysis. Patients were divided into three groups-GI <1 year, GII 1-5 years, GIII 5-13 years of dialysis and were compared with 22 controls. Increase by 34% of triacylglycerols (TG) was noted in GI and by 36% in GII versus GI. Hypertriglyceridemia was correlated with hemodialysis duration (HD) (r=0.75, P<0.05). The LCAT activity decrease by 25% was noted in GII versus GI (P<0.05) and by 45% in GIII versus GI (P<0.01), this activity was negligible in 33% of GII and 39% of GIII. LCAT activity was negatively correlated with HD (r=-0.80, P<0.001). Hemodialysis duration did not influence HDL(3) and HDL(2) amounts, HDL(3)-phospholipids (PL), HDL(3) and HDL(2)-cholesteryl esters (CE) and HDL(2)-apolipoproteins. However, an increase by 56% in HDL(2)-PL was noted in GIII versus GI and GII (P<0.01). HDL(2)-unesterified cholesterol (UC) were 2-fold higher in GIII than GII and GI (P<0.01). HDL(2)-TG were 2.2-fold higher in GII and 2.4-fold in GIII than GI (P<0.001). HDL(3)-apolipoproteins were 1.5-fold and 1.8-fold lower in GI than GII (P<0.05) and GIII (P<0.01), respectively. An increase in HDL(3)-UC by 20% in GII and 33% in GIII versus GI (P<0.01) was noted. HDL(3)-TG increase by 66% was noted in GII and GIII versus GI (P<0.05). We conclude, that the long-term hemodialysis does not act on lipid anomalies following CRF. Alterations in HDL composition contribute to the reduced efficacy of reverse cholesterol transport, which is a risk factor for cardiovascular disease.
authors: Laboratoire de Nutrition Clinique et Métabolique, Département de biologie, Faculté des Sciences, Université d'Oran-31100, Es-Senia, Algeria.
authors: Khedidja
authors: K
authors: Mekki
authors: Malika
authors: M
authors: Bouchenak
authors: Myriem
authors: M
authors: Lamri
authors: Mustapha
authors: M
authors: Remaoun
authors: Jacques
authors: J
authors: Belleville
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy*; D008075:Lipoproteins, HDL / Q000097:blood*; D053439:Lipoproteins, HDL2; D053440:Lipoproteins, HDL3; D008297:Male; D008875:Middle Aged; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000097:blood*; D006435:Renal Dialysis; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D008075:Lipoproteins, HDL; D053439:Lipoproteins, HDL2; D053440:Lipoproteins, HDL3; D014280:Triglycerides; D007862:Phosphatidylcholine-Sterol O-Acyltransferase